严重的α-1抗素缺乏症的增强疗法改善了生存率,并与螺旋计下降脱 - - 一个跨国注册分析
Daniel D Fraughen1, Auyon J Ghosh2, Brian D Hobbs3
1Department of Medicine, Irish Center for Genetic Lung Disease, Royal College of Surgeons in Ireland, Dublin, Ireland.
American journal of respiratory and critical care medicine
|August 25, 2023
概括
静脉输入的α-1抗素 (IV-AAT) 治疗改善了严重的α-1抗素缺乏症 (AATD) 的生存率. 虽然它没有影响FEV1总体下降,但它有利于特定的患者表型,特别是GOLD阶段2的患者.
科学领域:
- 肺部病理学 肺部病理学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 自1987年以来,静脉注射α-1抗素 (IV-AAT) 已成为治疗α-1抗素缺乏症 (AATD) 的疗法.
- 之前的试验表明IV-AAT可以保持肺密度,但不能保持FEV1.
- 这项研究研究了爱尔兰,瑞士和奥地利严重AATD患者的真实IV-AAT效应.
研究的目的:
- 评估IV-AAT治疗在患有严重AATD的个体中的真实世界的纵向效应.
- 为了确定潜在的生存益处和对肺功能的影响.
- 探索AATD表型及其对IV-AAT的反应.
主要方法:
- 肺功能和死亡率数据的纵向分析来自615名严重AATD参与者的登记.
- 基于AATD表型 (肺指数与非肺指数) 的结果比较.
- 在全球慢性阻塞性肺病倡议 (GOLD) 的不同阶段,对IV-AAT对FEV1下降的影响的评估.
主要成果:
- 在严重的AATD中,IV-AAT治疗提供了显著的生存优势 (P < 0.001).
- 确定了两个不同的AATD表型:肺指数和非肺指数,具有不同的FEV1下降模式.
- IV-AAT没有影响FEV1的下降,除了肺指数GOLD阶段2的患者,他们显示了减弱的下降.
结论:
- 现实世界的数据证实了与IV-AAT相关的生存益处在严重的AATD中,在很大程度上独立于FEV1变化.
- 鉴定两个AATD表型对临床试验设计有影响,因为典型的参与者可能不会表现出螺旋变化.
- IV-AAT显示,它有可能减缓特定患者群体 (GOLD第二阶段肺指数) 的螺旋体衰退,而这些患者群体目前并非标准推的目标.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
263
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
263
Acute Respiratory Failure-V
162
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
162
COPD: Management Using Bronchodilators and Corticosteroids
244
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
244
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
Cystic Fibrosis: Management
194
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
194


